Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (191-200 of 420) with videos related to

Pageof 42
Sort By:
Diagnostic Microbiology and Infectious Disease|August 20, 2011
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)Rodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|February 10, 2006
Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004)Paul R Rhomberg, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2004
Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolatesHelio S Sader, Jennifer M Streit, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|February 20, 2004
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolatesJennifer M Streit, Thomas R Fritsche, Helio S Sader, et al.
International Journal of Antimicrobial Agents|December 29, 2004
Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infectionsHelio S Sader, Douglas J Biedenbach, Jennifer M Streit, et al.
Diagnostic Microbiology and Infectious Disease|November 28, 2018
In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016)Leonard R Duncan, Robert K Flamm, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unitHelio S Sader, Ronald N Jones, Michael J Dowzicky, et al.
The Journal of Antimicrobial Chemotherapy|September 18, 2010
Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumoniaMichael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2013
More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USARonald N Jones, Helio S Sader, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|October 14, 2009
Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007)Ronald N Jones, Matthew G Stilwell, Paul R Rhomberg, et al.
Pageof 42

Showing results (191-200 of 420) with videos related to

Sort By:
Pageof 42
Diagnostic Microbiology and Infectious Disease|August 20, 2011
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)Rodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|February 10, 2006
Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004)Paul R Rhomberg, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2004
Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolatesHelio S Sader, Jennifer M Streit, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|February 20, 2004
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolatesJennifer M Streit, Thomas R Fritsche, Helio S Sader, et al.
International Journal of Antimicrobial Agents|December 29, 2004
Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infectionsHelio S Sader, Douglas J Biedenbach, Jennifer M Streit, et al.
Diagnostic Microbiology and Infectious Disease|November 28, 2018
In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016)Leonard R Duncan, Robert K Flamm, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unitHelio S Sader, Ronald N Jones, Michael J Dowzicky, et al.
The Journal of Antimicrobial Chemotherapy|September 18, 2010
Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumoniaMichael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2013
More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USARonald N Jones, Helio S Sader, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|October 14, 2009
Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007)Ronald N Jones, Matthew G Stilwell, Paul R Rhomberg, et al.
Pageof 42